Home

GoodRx Appoints Christopher A. McGinnis as Chief Financial Officer

Published 4 hours ago via Business Wire

Seasoned industry executive brings decades of financial strategy and leadership experience to GoodRx

GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role.

Chris will join GoodRx following his role as CEO of CitizensRx, where he led the company in providing pharmacy benefit management services to commercial clients. Before that, Chris held various executive roles at Lumeris / Essence Healthcare, a Medicare Advantage plan and value-based healthcare operator, including serving as its Chief Financial Officer and Executive Vice President of Operations where he oversaw all aspects of health plan operations, value-based services, and technology. Prior to that, as Chief Accounting Officer at Express Scripts Holding Company, Chris had overall responsibility for accounting, SEC reporting and compliance, tax strategy and investor relations for one of the largest pharmacy benefit managers in the country.

“I’m thrilled to welcome Chris to the team and know that his deep financial expertise and strong healthcare track record will prove to be an incredibly valuable asset for the company,” said Wendy Barnes, Chief Executive Officer and President of GoodRx. “I had the privilege of working alongside Chris during his tenure at Express Scripts and know he is uniquely equipped to help guide GoodRx through its next phase of growth. I look forward to working together again to help remove the friction Americans face when getting their medications.”

"I am excited to join GoodRx and help lead the company’s efforts to make healthcare easier to understand and more affordable for millions of Americans," said Chris McGinnis, the newly appointed Chief Financial Officer of GoodRx. “I’ve witnessed firsthand that the pharmacy industry needs a complementary solution to a fragmented structure that enables consumers to easily fill their medications. I believe GoodRx is well-positioned to deliver on these promises, and I look forward to working with a talented leadership team to drive growth and deliver stakeholder value.”

About GoodRx

GoodRx is the leading prescription savings platform in the U.S. Trusted by nearly 30 million consumers and over one million healthcare professionals annually, GoodRx provides access to savings and affordability options for generic and brand-name medications at more than 70,000 pharmacies nationwide, as well as comprehensive healthcare research and information. Since 2011, GoodRx has helped consumers save over $75 billion on the cost of their prescriptions.

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, the statements regarding anticipated future performance of the Company and expected benefits to the Company related to this Chief Financial Officer appointment. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contacts